vs
Citi Trends Inc（CTRN）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Citi Trends Inc的1.1倍（$207.3M vs $197.1M），Citi Trends Inc净利率更高（-3.5% vs -62.0%，领先58.5%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 10.1%），Citi Trends Inc自由现金流更多（$767.0K vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -4.3%）
Citi Trends Inc是一家美国服装零售连锁品牌，主营折扣服饰商品，目标客群以非裔美国人为主，凭借高性价比的产品策略在美国本土折扣零售市场占据一席之地。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CTRN vs RARE — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $197.1M | $207.3M |
| 净利润 | $-6.9M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | -3.7% | -54.7% |
| 净利率 | -3.5% | -62.0% |
| 营收同比 | 10.1% | 25.9% |
| 净利润同比 | 3.6% | 3.5% |
| 每股收益（稀释后） | $-0.86 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $197.1M | $207.3M | ||
| Q3 25 | $190.8M | $159.9M | ||
| Q2 25 | $201.7M | $166.5M | ||
| Q1 25 | $211.2M | $139.3M | ||
| Q4 24 | $179.1M | $164.6M | ||
| Q3 24 | $176.6M | $139.5M | ||
| Q2 24 | $186.3M | $147.0M | ||
| Q1 24 | $215.2M | $108.8M |
| Q4 25 | $-6.9M | $-128.6M | ||
| Q3 25 | $3.8M | $-180.4M | ||
| Q2 25 | $871.0K | $-115.0M | ||
| Q1 25 | $-14.2M | $-151.1M | ||
| Q4 24 | $-7.2M | $-133.2M | ||
| Q3 24 | $-18.4M | $-133.5M | ||
| Q2 24 | $-3.4M | $-131.6M | ||
| Q1 24 | $3.6M | $-170.7M |
| Q4 25 | -3.7% | -54.7% | ||
| Q3 25 | 1.8% | -106.9% | ||
| Q2 25 | 0.2% | -64.8% | ||
| Q1 25 | 0.6% | -102.6% | ||
| Q4 24 | -4.9% | -74.3% | ||
| Q3 24 | -14.1% | -94.6% | ||
| Q2 24 | -3.7% | -79.1% | ||
| Q1 24 | 1.8% | -151.9% |
| Q4 25 | -3.5% | -62.0% | ||
| Q3 25 | 2.0% | -112.8% | ||
| Q2 25 | 0.4% | -69.0% | ||
| Q1 25 | -6.7% | -108.5% | ||
| Q4 24 | -4.0% | -80.9% | ||
| Q3 24 | -10.4% | -95.7% | ||
| Q2 24 | -1.8% | -89.5% | ||
| Q1 24 | 1.7% | -156.8% |
| Q4 25 | $-0.86 | $-1.28 | ||
| Q3 25 | $0.46 | $-1.81 | ||
| Q2 25 | $0.11 | $-1.17 | ||
| Q1 25 | $-1.70 | $-1.57 | ||
| Q4 24 | $-0.86 | $-1.34 | ||
| Q3 24 | $-2.21 | $-1.40 | ||
| Q2 24 | $-0.42 | $-1.52 | ||
| Q1 24 | $0.43 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $107.8M | $-80.0M |
| 总资产 | $464.3M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $107.8M | $-80.0M | ||
| Q3 25 | $113.2M | $9.2M | ||
| Q2 25 | $108.6M | $151.3M | ||
| Q1 25 | $113.2M | $144.2M | ||
| Q4 24 | $130.3M | $255.0M | ||
| Q3 24 | $136.6M | $346.8M | ||
| Q2 24 | $154.8M | $432.4M | ||
| Q1 24 | $157.7M | $140.3M |
| Q4 25 | $464.3M | $1.5B | ||
| Q3 25 | $457.4M | $1.2B | ||
| Q2 25 | $437.4M | $1.3B | ||
| Q1 25 | $462.8M | $1.3B | ||
| Q4 24 | $467.1M | $1.5B | ||
| Q3 24 | $506.7M | $1.5B | ||
| Q2 24 | $484.1M | $1.6B | ||
| Q1 24 | $518.7M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.6M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $767.0K | $-100.8M |
| 自由现金流率自由现金流/营收 | 0.4% | -48.6% |
| 资本支出强度资本支出/营收 | 4.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $11.9M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $8.6M | $-99.8M | ||
| Q3 25 | $3.9M | $-91.4M | ||
| Q2 25 | $-11.0M | $-108.3M | ||
| Q1 25 | $28.5M | $-166.5M | ||
| Q4 24 | $-18.4M | $-79.3M | ||
| Q3 24 | $5.6M | $-67.0M | ||
| Q2 24 | $-19.6M | $-77.0M | ||
| Q1 24 | $23.3M | $-190.7M |
| Q4 25 | $767.0K | $-100.8M | ||
| Q3 25 | $-1.7M | $-92.7M | ||
| Q2 25 | $-13.1M | $-110.7M | ||
| Q1 25 | $26.0M | $-167.8M | ||
| Q4 24 | $-20.4M | $-79.5M | ||
| Q3 24 | $1.7M | $-68.6M | ||
| Q2 24 | $-21.2M | $-79.0M | ||
| Q1 24 | $20.0M | $-193.9M |
| Q4 25 | 0.4% | -48.6% | ||
| Q3 25 | -0.9% | -58.0% | ||
| Q2 25 | -6.5% | -66.5% | ||
| Q1 25 | 12.3% | -120.5% | ||
| Q4 24 | -11.4% | -48.3% | ||
| Q3 24 | 0.9% | -49.2% | ||
| Q2 24 | -11.4% | -53.7% | ||
| Q1 24 | 9.3% | -178.2% |
| Q4 25 | 4.0% | 0.5% | ||
| Q3 25 | 2.9% | 0.8% | ||
| Q2 25 | 1.0% | 1.5% | ||
| Q1 25 | 1.2% | 1.0% | ||
| Q4 24 | 1.1% | 0.1% | ||
| Q3 24 | 2.2% | 1.2% | ||
| Q2 24 | 0.9% | 1.4% | ||
| Q1 24 | 1.5% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | 1.01× | — | ||
| Q2 25 | -12.59× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 6.56× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTRN
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
